Stock BCLI BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 07:10:06 29/04/2024 pm IST 		5-day change 1st Jan Change
0.54 USD +1.03% Intraday chart for Brainstorm Cell Therapeutics Inc. +0.47% +95.79%
17/04 Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 CI
17/04 Brainstorm Cell Therapeutics Inc. Announces Management Changes CI

Business Summary

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Number of employees: 29

Managers

Managers TitleAgeSince
Chaim Lebovits CEO
 Chief Executive Officer 53 01/07/01
Alla Patlis DFI
 Director of Finance/CFO 37 23/12/23
Netta Blondheim-Shraga CTO
 Chief Tech/Sci/R&D Officer - 12/22/12
Bob Dagher CTO
 Chief Tech/Sci/R&D Officer 55 17/23/17
Yael Gothelf CTO
 Chief Tech/Sci/R&D Officer - 01/07/01
Stacy Lindborg BRD
 Director/Board Member 53 01/20/01
Uri Yablonka BRD
 Director/Board Member 47 06/14/06
Antal Pearl-Lendner LAW
 General Counsel - 12/22/12
Mary Kay Turner LAW
 General Counsel - 07/17/07
Yossef Levy PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Irit Arbel FOU
 Founder 64 22/00/22
Uri Yablonka BRD
 Director/Board Member 47 06/14/06
Jacob Frenkel CHM
 Chairman 81 30/20/30
Menghisteab Bairu BRD
 Director/Board Member 63 28/21/28
Anthony J. Polverino BRD
 Director/Board Member 61 05/18/05
Stacy Lindborg BRD
 Director/Board Member 53 01/20/01
Nir Naor BRD
 Director/Board Member 50 20/23/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,341,857 59,284,308 ( 86.75 %) 0 86.75 %

Shareholders

NameEquities%Valuation
Kevin Ness
6.247 %
3,060,000 6.247 % 2 M $
Chaim Lebovits
5.838 %
2,859,412 5.838 % 2 M $
Abbhi Investments LLC
4.442 %
2,175,853 4.442 % 1 M $
Vanguard Global Advisers LLC
2.906 %
1,423,310 2.906 % 804 170 $
BlackRock Institutional Trust Co. NA
0.9392 %
460,027 0.9392 % 259 915 $
Stacy Lindborg
0.8645 %
423,435 0.8645 % 239 241 $
Geode Capital Management LLC
0.7289 %
357,041 0.7289 % 201 728 $
Liberty Wealth Management LLC
0.6944 %
340,150 0.6944 % 192 185 $
Bob Dagher
0.5165 %
253,000 0.5165 % 142 945 $
Weaver Consulting Group LLC
0.4070 %
199,356 0.4070 % 112 636 $

Company contact information

Brainstorm Cell Therapeutics, Inc.

1325 Avenue of Americas 28th floor

10019, New York

+201 488 0460

http://www.brainstorm-cell.com
address Brainstorm Cell Therapeutics Inc.(BCLI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5345 USD
Average target price
2.5 USD
Spread / Average Target
+367.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BRAINSTORM CELL THERAPEUTICS INC. Stock Brainstorm Cell Therapeutics Inc.
+95.79% 36.53M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.20% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. Company Brainstorm Cell Therapeutics Inc.